Extra domain A-positive fibronectin-positive feedback loops and their association with cutaneous inflammatory disease

Clinics in Dermatology

Volumn 29, Issue 3, 2011, Pages 257-265

  McFadden, John P ^a   Basketter, David A ^a   Dearman, Rebecca J ^b   Kimber, Ian R ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; EXTRA DOMAIN A POSITIVE FIBRONECTIN; FIBRINOGEN; FIBRONECTIN; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEPARAN SULFATE; HIGH MOBILITY GROUP B1 PROTEIN; HYALURONIC ACID; MESSENGER RNA; SINGLE STRANDED RNA; SURFACTANT PROTEIN A; TENASCIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNITY; CELL PROLIFERATION; DOWN REGULATION; HUMAN; KERATINOCYTE; PATHOPHYSIOLOGY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; SIGNAL TRANSDUCTION; SKIN ALLERGY; TH1 CELL; TH17 CELL;

DERMATITIS; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; FIBRONECTINS; HUMANS; PSORIASIS; SIGNAL TRANSDUCTION; TH1 CELLS; TH17 CELLS; TOLL-LIKE RECEPTOR 4;

EID: 79954495815     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2010.11.003     Document Type: Article

References (72)

1. Vance R.E., Isberg R.R., Portnoy D.A. Patterns of pathogenesis: discrimination of the pathogenic and non-pathogenic microbes by the innate immune system. Cell Host Microbe 2009, 6:10-21.
2. Gill R., Tsung A., Billiar T.R. Linking oxidative stress to inflammation: Toll-like receptors. Free Rad Bio Med 2010, 48:1121-1132.
3. Okamura Y., Watari M., Jerud E.S., et al. The extradomain A of fibronectin activates Toll-like receptor 4 J. Biol Chem 2001, 276:10229-10233.
4. Szell M., Bata-Csorgo Z., Koreck A., et al. Proliferating keratinocytes are putative sources of the psoriasis susceptibility-related EDA+ (extra domain A of fibronectin) oncofetal fibronectin. J Invest Dermatol 2004, 123:537-546.
5. McFadden J.P., Baker B.S., Powles A.V., Fry L. Psoriasis and extradomain A fibronectin loops. Br J Dermatol 2010, 163:5-11.
6. Valdimarsson H., Thorleifsdottir R.H., Sigurdardottir S.L., et al. Psoriasis- as an autoimmune disease caused by molecular mimicry. Trends Immunol 2009, 30:494-501.
7. Tsan M., Gao B. Endogenous ligands of Toll-like receptors. J Leuk Biol 2004, 76:514-519.
8. Papdimitraki E.D., Bertsias G.K., Boumpas D.T. Toll like receptors and autoimmunity: a critical appraisal. J Autoimmun 2007, 29:310-318.
9. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
10. Poltorak A., He X., Smirnova I., et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
11. Ohashi K., Burkant V., Flohe S., Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 2000, 164:558-561.
12. Dennehy K.M., Willment J.A., Williams D.L., Brown G.D. Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signalling pathways. Eur J Immunol 2009, 39:1379-1386.
13. White E., Baralee F.E., Muro A.F. New insights into form and function of fibronectin splice variants. J Pathol 2008, 216:1-14.
14. Sereni G., Valdembri D., Bussolini F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006, 312:651-658.
15. Leon C.G., Tory R., Jia J., et al. Discovery and development of Toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharamceut Res 2008, 258:1751-1761.
16. Rifkin I.R., Leadbetter E.A., Busconi L., et al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27-42.
17. Lasarte J.J., Casares N., Gorrlaz M., et al. Extra-domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007, 178:748-753.
18. Sandig H., McDonald J., Gilmour J., et al. Fibronectin is a T(H)1-specific molecules in human subjects. J Allergy Clin Immunol 2009, 124:528-553.
19. Bata-Csorgo Z., Cooper K., Ting K., et al. Fibronectin and α5 integrin regulate keratinocyte cell cycling. J Clin Invest 1998, 101:1509-1518.
20. Manabe R.I., Oh-e Maeda T., et al. Modulation of cell adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol 1997, 139:295-307.
21. Manabe R.I., Oh-e N., Sekiguchi K. Alternatively spliced EDA segment regulates fibronectin-dependant cell cycle progression and mitogenic signal transduction. J Biol Chem 1999, 274:5919-5924.
22. Bata-Csorgo Z., Hammerberg C., Voorhees J.J., Cooper K.D. Kinetics and regulation of human keratinocyte growth in short-term primary ex-vivo culture. Co-operative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved but not normal keratincoytes. J Clin Invest 1995, 95:317-327.
23. Leask A., Abraham D.J. TGF-beta signalling and the fibrotic response. FASEB J 2004, 18:816-827.
24. Groves R.W., Allen M.H., Ross E.L., et al. Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 1995, 132:530-534.
25. Nestle F.O., Kaplan D.H., Barker J.N. Psoriasis. New Engl J Med 2009, 361:496-509.
26. Deng J., Ma-Krup W., Gerwitz A.T., et al. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res 2009, 104:488-495.
27. Antonelli A., Fallahi P., Dellle Sedie A., et al. High values of Th1(CXCL10) and Th2 (CCL2) chemokines in patients with psoriasis. Clin Exp Rheumatol 2009, 27:22-27.
28. Lee C.H., Wu C.L., Shiau A.L. Toll-like receptor 4 mediates antitumour host response by salmonella choleraesuis. Clin Can Res 2008, 14:1905-1912.
29. Hartmann B., Staedtler F., Hartmann N., et al. Gene expression profiling of skin and draining lymph nodes of rats affected with cutaneous contact hypersensitivity. Inflamm Res 2006, 55:322-324.
30. Smiley A.K., Klingenberg J.M., Boyce S.T., Supp D.M. Keratin expression in cultured skin substitutes suggest that the hyperproliferative phenotype observed in vitro is normalised after grafting. Burns 2006, 32:135-138.
31. McFadden J.P., Valdimarsson H., Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol 1991, 125:443-447.
32. Duffin K.C., Woodcock J., Krueger G.G. Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatologic Therapy 2010, 23:101-113.
33. Chang Y.T., Chou C.T., Shiao Y.M., et al. Psoriasis vulgaris in Chinese individuals is associated with PSOR1C3 and CDSN genes. Br J Dermatol 2006, 155:663-669.
34. Coto-Segura P., Coto E., Alvarez V., et al. Apolipoprotein epsilon4 allele is associated with psoriasis severity. Arch Dermatol Res 2010, 302:145-149.
35. Dubey D.P., Alper C.A., Mirza N.M., et al. Polymorphic Hh genes in the HLA-B(C) region control natural killer cell frequency and activity. J Exp Med 1994, 179:1193-1203.
36. Danik J.S., Pare G., Chasman D.I., et al. Novel loci, including those related to Crohn's disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17686 women; the Women's Genome Health Study. Circ Cardiovasc Genet 2009, 2:134-141.
37. Elder J.T., Bruce A.T., Gudjonsson J.E., et al. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010, 130:1213-1226.
38. Gudjonsson J.E., Johnston A., Sigmunsdottir H., Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004, 135:1-8.
39. Sarkar F.H., Li Y., Wang Z., Kong D. NF-kappaB signalling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008, 27:293-319.
40. Settin A., Hassan H., El-Baz R., Hassan T. Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt. Acta Dermatovenereol Alp Panonica Adriat 2009, 18:105-112.
41. Zervou M.I., Goulieimos G.N.B., Castro-Giner F., et al. STAT$ gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece. Hum Immunol 2009, 70:738-741.
42. Zhang H., An J., Jiang Z., et al. Linkage of the genes controlling natural killer cell activity to HLA-B. Zhongua Yi Xue Yi Yi Chuan Xue Za Zhi 2000, 17:188-191.
43. Martin AP Gagliardi J., Baena-Cagnani C.E., et al. Expression of CS-1 fibronectin precedes monocyte chemoattractant protein-1 production during elicitation of allergic contact dermatitis. Clin Exp Allergy 2003, 33:1118-1124.
44. Liu N., Chen Y., Huang X. Fibronectin E111A splicing variant: A useful contribution to forensic wounding interval estimation. Forensic Sci Int 2006, 162:178-182.
45. Martin S.F., Dudda J.C., Bachtanian E., et al. Toll-like receptor and IL-12 signalling control susceptibility to contact hypersensitivity. J Exp Med 2008, 205:2151-2162.
46. Schuetze N.S., Schoeneberger U., Mueller M.A., et al. IL-12 family members; differential kinetics of their TLR-4 mediated induction by Salmonella enteritidis and the impact of IL10 in bone marrow-derived macrophages. Int Immunol 2005, 17:649-659.
47. Wahbi A.H., Marcusson J.A., Sundqvist K.G. Expression of adhesion molecules and their ligands in contact allergy. Exp Allergy 1996, 5:12-19.
48. Yusuf N., Nasti T.H., Huang C.M., et al. Heat shock proteins HSP27 and HSP70 are present in the skin and are important mediators of allergic contact hypersensitivity. J Immunol 2009, 182:675-683.
49. Morioka Y., Yamasaki K., Leung D., Gallo R.L. Cathelcidin antimicrobial peptides inhibit hyaluronan-induced cytokine release and modulate chronic allergic dermatitis. J Immunol 2008, 181:3915-3922.
50. Gober M.D., Gaspari A.A. Allergic contact dermatitis. Curr Dir Autoimmun 2008, 10:1-26.
51. Coulter E.M., Jenkinson C., Farrell J., et al. Measurement of CD4+ and CD8+ T-lymphocyte cytokine secretion and gene expression changes in p-phenylenediamine allergic patients and tolerant individuals. J Invest Dermatol 2010, 130:161-174.
52. Wu C., Chie P., Hsieh H., et al. TLR4-dependant induction of vascular adhesion molecule-1 in rheumatoid arthritis synovial fibroblasts. J Cell Physiol 2010, 223:480-491.
53. O'Neill L.A., Bryant C.E. Doyle Sl. Therapeutic targeting of toll-like receptors for infections and inflammatory diseases and cancer. Pharmacol Rev 2009, 61:177-197.
54. Przbysz M., Borysewicz K., Katnik-Prastowska I. Differences between the early and advanced stages of rheumatoid arthritis in the expression of EDA-containing fibronectin. Rheumatol Int 2009, 29:1397-1401.
55. Katsargyris A., Theocharis S.E., Tsiodras S., et al. Enhanced TLR4 endothelial cell immunohistochemical expression in symptomatic carotid atherosclerotic plaques. Exper Opin Ther Targets 2010, 14:1-10.
56. Babaev V.R., Porro F., Linton M.F., et al. Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis 2008, 197:534-540.
57. Mueller T., Terada T., Rodenberg I.M., et al. Th2 cytokines down-regulates TLR expression and function in human intestinal epithelial cells. J Immunol 2006, 176:5805-5814.
58. Fiset P.O., Tulic M.K., Skrablin P.S., et al. Signal transducer and activator of transcription 6 down-regulates toll-like receptor-4 expression of a monocytic cell line. Clin Exp Allergy 2006, 36:158-165.
59. Ke B., Shen X.D., Gao F., et al. Interleukin 13 gene transfer in liver ischaemia and reperfusion injury: role of Stat6 and TLR4 pathways in cryoprotection. Hum Gen Ther 2004, 15:691-698.
60. Siwiec J., Zaborowski T., Jankowska O., et al. Evaluation of Th1/Th2 lymphocyte balance and lipopolysaccharide receptor expression in asthma patients. Pneumonol Allergol Pol 2009, 77:123-130.
61. Wang L., Liu Q., Sun Q., et al. TLR4 signalling in cancer cells promotes chemoattraction of immature dendritic cells via autocrine CCL20. Biochem Biophys Res Coomun 2008, 366:852-856.
62. Dittrich A.M., Chen H.C., Xu L., et al. A new mechanism for inhalational priming; Il-4 bypasses innate immune signals. J Immunol 2008, 181:3707-3715.
63. Novak H., Muller A., Harrer N., et al. CCL23 expression is induced by Il-4 in a STAT6-dependant fashion. J Immunol 2007, 178:4335-4341.
64. Nomura I., Gao B., Boguniewicz M., et al. Distinct pattern of gene expression in the skin lesions of atopic dermatitis: a gene microarray analysis. J Allergy Clin Immunol 2003, 112:1195-1202.
65. Ong P.Y. Leung DY The chemokine receptor CCR6 identifies interferon-gamma expressing T cells and s decreased in atopic dermatitis as compared to psoriasis. J Invest Dermatol 2002, 119:1463-1464.
66. Vassiliou E., Jiang X., Delgado M., Ganea D. Th2 lymphocytes secrete functional VIP upon antigen stimulation. Arch Physiol Biochem 2001, 109:365-368.
67. Sharma V., Delgadom Ganea D. VIP protects Th2 cells by downregulating granzyme B expression. J Immunol 2006, 176:97-110.
68. Arranz A., Gutierrez-Canas I., Carrion M., et al. VIP reverses the expression profiling of TLR4-stimulatd signalling pathway in rheumatoid arthritis synovial fibroblasts. Mol Immunol 2008, 45:3065-3073.
69. Jiang X., Jing H., Ganea D. VIP and PACAP down-regulate CXCL-10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J Neuroimmunol 2002, 133:81-94.
70. Liu L., Jui-Hung Y., Ganea D. A novel VIP signalling pathway in T cells; cAMP-protein tyrosine phosphatase- JAK2/STAT4- Th1 differentiation. Peptides 2007, 28:1814-1824.
71. Gutiérrez-Cañas I., Juarranz Y., Santiago B., et al. Immunoregulatory properties of vasoactive intestinal peptide inhuman T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun 2008, 22:312-317.
72. Ogasawara M., Murata J., Kamitani Y., et al. Inhibition by vasoactive intestinal polypeptide (VIP) of angiogenesis induced by murine colon 26-L5 carcinoma cells metastasized by liver. Clin Exp Metastasis 1999, 17:283-291.